Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

adenovirus 5 CEA/MUC1/brachyury vaccine Tri-Ad5

A combination of three therapeutic cancer vaccines each containing a replication-defective, oncolytic adenoviral serotype 5 (Ad5) and each encoding a different tumor-associated antigen (TAA): human carcinoembryonic antigen (CEA), human glycoprotein mucin 1 (MUC1), and human transcription factor brachyury, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the Ad5 CEA/MUC1/brachyury vaccine Tri-Ad5 expresses the CEA, MUC1 and brachyury proteins. The expressed proteins may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing CEA, MUC1 and brachyury, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. CEA, MUC1 and brachyury are TAAs overexpressed in various tumor types. The Ad5 viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) are deleted in Tri-Ad5, which prevents anti-adenovirus immune responses.
Synonym:Ad5 CEA/MUC1/brachyury vaccine Tri-Ad5
Ad5-CEA/Ad5-MUC1/Ad5-brachyury vaccine Tri-Ad5
adenoviral CEA/MUC1/brachyury vaccine Tri-Ad5
Code name:Tri Ad5
Tri-Ad5
TriAd5
Search NCI's Drug Dictionary